TP53 and cancer: Such SAH-p53 peptides exhibit significantly high affinity for MDM2/X in contrast to the corresponding native p53 peptide, and improve the cell permeability and increased helical stability compared to the peptidomimetics, therefore, they are becoming a new trend of anti-cancer drug development.